Table 1.

Potential targetable driver mutations in squamous cell carcinoma of the lung

GeneFrequency (%)DrugReference
FGFR1 amplification22FGFR TKIsWeiss et al. (6)
EGFRvIII mutations5EGFR TKIsJi et al. (10)
PIK3CA mutations3.6PI3K inhibitorsYamamoto et al. (11)
EGFR kinase domain mutations3.4EGFR TKIsMiyamae et al. (12)
DDR2 mutations3.2Dasatinib, nilotinibHammerman et al. (1)
  • Abbreviation: TKI, tyrosine kinase inhibitor.